Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $88.89

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average recommendation of “Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $88.89.

Several equities analysts have issued reports on KROS shares. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Scotiabank assumed coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective on the stock. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, Guggenheim began coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company.

Keros Therapeutics Trading Up 1.2 %

Shares of NASDAQ KROS opened at $56.58 on Friday. Keros Therapeutics has a 12-month low of $27.31 and a 12-month high of $73.00. The stock’s fifty day simple moving average is $59.32 and its two-hundred day simple moving average is $52.16. The stock has a market capitalization of $2.29 billion, a PE ratio of -10.86 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. On average, equities analysts predict that Keros Therapeutics will post -5.28 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Keros Therapeutics by 7.9% in the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after purchasing an additional 113,563 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the last quarter. American International Group Inc. grew its holdings in shares of Keros Therapeutics by 13.1% in the first quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after purchasing an additional 1,465 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after purchasing an additional 2,822 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Keros Therapeutics by 17.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after purchasing an additional 176,803 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.